Concord Drugs posts Rs 7.35 crore operating cash outflow

Concord Drugs Limited reported a consolidated operating cash outflow of Rs 7.35 crore for the six months ended September 30, 2026, despite profit after tax of Rs 2.21 crore, as a Rs 15.69 crore rise in trade receivables and a Rs 5.93 crore increase in other current assets absorbed cash.

Why did Concord Drugs report an operating cash outflow?

Concord Drugs reported an operating cash outflow because working-capital movements exceeded cash generated before those changes. Its consolidated operating profit before working-capital changes was Rs 4.65 crore for the six months ended September 30, 2026, but cash generated from operations became negative Rs 6.49 crore after movements in operating assets and liabilities.

Trade receivables were the biggest cash use, rising by Rs 15.69 crore in the consolidated cash-flow statement. Other current assets increased by Rs 5.93 crore, loans and advances rose by Rs 1.03 crore, and other current financial assets rose by Rs 31.10 lakh. These increases used more cash than was released by lower inventory and higher trade payables.

Net income tax paid was Rs 85.67 lakh, taking the consolidated net cash outflow from operating activities to Rs 7.35 crore. The cash-flow statement's column labelled March 31, 2026 showed an operating outflow of Rs 6.77 crore, compared with the Rs 7.35 crore outflow reported for September 30, 2026.

The reported outflow therefore reflected the timing of collections, advances and current-asset movements rather than a loss in the half year. Concord Drugs recorded Rs 4.65 crore of operating profit before working-capital changes, but the combined rise in receivables and other current assets was Rs 21.62 crore, before considering the Rs 1.03 crore increase in loans and advances.

How did Concord Drugs' profit differ from its cash generation?

Concord Drugs earned consolidated profit after tax of Rs 2.21 crore for the six months ended September 30, 2026, while its operating cash flow was negative Rs 7.35 crore. Profit before tax was Rs 3.05 crore, showing that the cash deficit arose after accounting profit was adjusted for non-cash items, financing costs and working-capital changes.

Revenue from operations was Rs 41.69 crore and other income was Rs 6.43 lakh, giving total revenue of Rs 41.76 crore. Total expenses were Rs 38.71 crore, leaving the Rs 3.05 crore profit before tax. The company reported tax expense of Rs 83.98 lakh, including a current-tax charge of Rs 85.67 lakh and deferred-tax credit of Rs 1.69 lakh.

Depreciation and amortisation of Rs 70.71 lakh and finance costs of Rs 95.28 lakh were added back in arriving at operating profit before working-capital changes. Interest income of Rs 6.43 lakh was also included among the cash-flow adjustments. These items helped reconcile profit before tax of Rs 3.05 crore to the Rs 4.65 crore operating-profit measure.

The reported consolidated column labelled March 31, 2026 showed profit after tax of Rs 1.06 crore and profit before tax of Rs 1.47 crore. Profit after tax was therefore Rs 1.16 crore higher in the September 30, 2026 column, while the operating cash outflow was Rs 58.06 lakh greater than the outflow shown in the March 31 column.

Which working-capital balances changed at Concord Drugs?

Concord Drugs' consolidated trade receivables increased to Rs 40.07 crore at September 30, 2026, from Rs 24.38 crore at March 31, 2026. That Rs 15.69 crore balance-sheet movement matched the largest cash-flow use and meant a greater amount was outstanding from customers at the reporting date.

Other current assets rose to Rs 8.56 crore from Rs 2.63 crore, a Rs 5.93 crore increase. Loans and advances increased to Rs 1.10 crore from Rs 7.89 lakh, while other current financial assets increased to Rs 34.87 lakh from Rs 3.77 lakh. Each of those balance increases was reflected as a use of operating cash.

Some working-capital movements partly offset those uses. Inventory declined to Rs 24.62 crore at September 30 from Rs 25.52 crore at March 31, releasing Rs 1.10 crore of cash. Trade payables increased to Rs 18.49 crore from Rs 7.07 crore, providing a Rs 11.43 crore cash-flow offset.

The asset and liability movements changed the composition of the balance sheet. Total current assets were Rs 74.15 crore at September 30, 2026, compared with Rs 53.31 crore at March 31, while total current liabilities were Rs 37.71 crore, compared with Rs 21.07 crore. The source does not disclose collection terms or the reasons for the receivables increase.

How did Concord Drugs fund the cash deficit?

Concord Drugs reported net financing cash inflow of Rs 7.74 crore for the six months ended September 30, 2026. That inflow exceeded the Rs 7.35 crore operating outflow and Rs 38.40 lakh investing outflow, leaving cash and cash equivalents at Rs 29.03 lakh at the end of the period.

The financing section includes Rs 5.49 crore under government grants, Rs 3.20 crore in a borrowing-related line, and Rs 95.28 lakh of finance costs. The cash-flow statement reports a financing inflow of Rs 7.74 crore after those movements. Its column labelled March 31, 2026 reported financing inflow of Rs 8.06 crore.

Consolidated non-current borrowings rose to Rs 5.01 crore at September 30, 2026, from Rs 1.81 crore at March 31. Current borrowings rose to Rs 17.29 crore from Rs 11.79 crore. Combined borrowings consequently increased to Rs 22.29 crore from Rs 13.60 crore, a rise of Rs 8.70 crore.

Investing activities used Rs 38.40 lakh, including Rs 44.84 lakh of capital expenditure on fixed assets and capital advances, partly offset by Rs 6.43 lakh of interest income. Cash and cash equivalents rose by Rs 1.21 lakh according to the cash-flow statement, from Rs 27.81 lakh at the beginning of the period to Rs 29.03 lakh at September 30, including Rs 28.94 lakh held with banks.

Conclusion

Concord Drugs' half-year results show that its Rs 2.21 crore consolidated profit did not convert into operating cash. The Rs 15.69 crore increase in trade receivables and Rs 5.93 crore rise in other current assets outweighed the Rs 11.43 crore increase in trade payables and the Rs 1.10 crore inventory reduction, producing a Rs 7.35 crore operating cash outflow.

The next results will show whether receivables of Rs 40.07 crore and other current assets of Rs 8.56 crore are collected or continue to expand, and whether borrowings remain above the Rs 22.29 crore reported at September 30, 2026. Concord Drugs' board approved the unaudited results on November 12, 2026, and said the financial results would be published in newspapers under listing requirements.